PortfoliosLab logoPortfoliosLab logo
LMAT vs. UTHR
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

LMAT vs. UTHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in LeMaitre Vascular, Inc. (LMAT) and United Therapeutics Corporation (UTHR). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

LMAT vs. UTHR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
LMAT
LeMaitre Vascular, Inc.
34.92%-10.95%63.63%24.60%-7.40%25.10%14.09%53.77%-25.13%26.58%
UTHR
United Therapeutics Corporation
21.70%38.09%60.46%-20.93%28.70%42.35%72.33%-19.12%-26.39%3.15%

Fundamentals

Market Cap

LMAT:

$2.51B

UTHR:

$28.40B

EPS

LMAT:

$2.47

UTHR:

$27.90

PE Ratio

LMAT:

44.28

UTHR:

21.25

PEG Ratio

LMAT:

1.91

UTHR:

0.70

PS Ratio

LMAT:

10.24

UTHR:

8.91

PB Ratio

LMAT:

6.37

UTHR:

4.00

Total Revenue (TTM)

LMAT:

$249.60M

UTHR:

$3.18B

Gross Profit (TTM)

LMAT:

$178.54M

UTHR:

$2.80B

EBITDA (TTM)

LMAT:

$85.42M

UTHR:

$1.82B

Returns By Period

In the year-to-date period, LMAT achieves a 34.92% return, which is significantly higher than UTHR's 21.70% return. Over the past 10 years, LMAT has outperformed UTHR with an annualized return of 22.62%, while UTHR has yielded a comparatively lower 18.04% annualized return.


LMAT

1D
2.15%
1M
1.15%
YTD
34.92%
6M
25.33%
1Y
31.31%
3Y*
29.74%
5Y*
18.74%
10Y*
22.62%

UTHR

1D
0.79%
1M
17.68%
YTD
21.70%
6M
41.45%
1Y
92.36%
3Y*
38.34%
5Y*
25.25%
10Y*
18.04%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LMAT vs. UTHR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LMAT
LMAT Risk / Return Rank: 7070
Overall Rank
LMAT Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
LMAT Sortino Ratio Rank: 7070
Sortino Ratio Rank
LMAT Omega Ratio Rank: 6969
Omega Ratio Rank
LMAT Calmar Ratio Rank: 7474
Calmar Ratio Rank
LMAT Martin Ratio Rank: 6868
Martin Ratio Rank

UTHR
UTHR Risk / Return Rank: 9393
Overall Rank
UTHR Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
UTHR Sortino Ratio Rank: 9494
Sortino Ratio Rank
UTHR Omega Ratio Rank: 9494
Omega Ratio Rank
UTHR Calmar Ratio Rank: 9595
Calmar Ratio Rank
UTHR Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LMAT vs. UTHR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for LeMaitre Vascular, Inc. (LMAT) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LMATUTHRDifference

Sharpe ratio

Return per unit of total volatility

0.80

1.84

-1.04

Sortino ratio

Return per unit of downside risk

1.55

3.30

-1.74

Omega ratio

Gain probability vs. loss probability

1.21

1.46

-0.25

Calmar ratio

Return relative to maximum drawdown

1.66

5.70

-4.04

Martin ratio

Return relative to average drawdown

3.00

14.49

-11.50

LMAT vs. UTHR - Sharpe Ratio Comparison

The current LMAT Sharpe Ratio is 0.80, which is lower than the UTHR Sharpe Ratio of 1.84. The chart below compares the historical Sharpe Ratios of LMAT and UTHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


LMATUTHRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.80

1.84

-1.04

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.52

0.72

-0.20

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.55

0.51

+0.03

Sharpe Ratio (All Time)

Calculated using the full available price history

0.36

0.39

-0.03

Correlation

The correlation between LMAT and UTHR is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

LMAT vs. UTHR - Dividend Comparison

LMAT's dividend yield for the trailing twelve months is around 0.78%, while UTHR has not paid dividends to shareholders.


TTM20252024202320222021202020192018201720162015
LMAT
LeMaitre Vascular, Inc.
0.78%1.23%0.69%0.99%1.09%0.88%0.94%0.95%1.18%0.69%0.71%0.93%
UTHR
United Therapeutics Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

LMAT vs. UTHR - Drawdown Comparison

The maximum LMAT drawdown since its inception was -75.69%, smaller than the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for LMAT and UTHR.


Loading graphics...

Drawdown Indicators


LMATUTHRDifference

Max Drawdown

Largest peak-to-trough decline

-75.69%

-93.18%

+17.49%

Max Drawdown (1Y)

Largest decline over 1 year

-19.91%

-16.35%

-3.56%

Max Drawdown (5Y)

Largest decline over 5 years

-37.93%

-33.00%

-4.93%

Max Drawdown (10Y)

Largest decline over 10 years

-47.65%

-55.56%

+7.91%

Current Drawdown

Current decline from peak

-3.75%

0.00%

-3.75%

Average Drawdown

Average peak-to-trough decline

-19.04%

-35.53%

+16.49%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.01%

6.43%

+4.58%

Volatility

LMAT vs. UTHR - Volatility Comparison

The current volatility for LeMaitre Vascular, Inc. (LMAT) is 7.72%, while United Therapeutics Corporation (UTHR) has a volatility of 17.05%. This indicates that LMAT experiences smaller price fluctuations and is considered to be less risky than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


LMATUTHRDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.72%

17.05%

-9.33%

Volatility (6M)

Calculated over the trailing 6-month period

27.47%

26.84%

+0.63%

Volatility (1Y)

Calculated over the trailing 1-year period

39.28%

50.41%

-11.13%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

36.27%

35.89%

+0.38%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

41.51%

35.32%

+6.19%

Financials

LMAT vs. UTHR - Financials Comparison

This section allows you to compare key financial metrics between LeMaitre Vascular, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
64.45M
790.20M
(LMAT) Total Revenue
(UTHR) Total Revenue
Values in USD except per share items

LMAT vs. UTHR - Profitability Comparison

The chart below illustrates the profitability comparison between LeMaitre Vascular, Inc. and United Therapeutics Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
71.7%
86.9%
Portfolio components
LMAT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, LeMaitre Vascular, Inc. reported a gross profit of 46.19M and revenue of 64.45M. Therefore, the gross margin over that period was 71.7%.

UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a gross profit of 686.80M and revenue of 790.20M. Therefore, the gross margin over that period was 86.9%.

LMAT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, LeMaitre Vascular, Inc. reported an operating income of 18.83M and revenue of 64.45M, resulting in an operating margin of 29.2%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported an operating income of 356.70M and revenue of 790.20M, resulting in an operating margin of 45.1%.

LMAT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, LeMaitre Vascular, Inc. reported a net income of 15.58M and revenue of 64.45M, resulting in a net margin of 24.2%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a net income of 364.30M and revenue of 790.20M, resulting in a net margin of 46.1%.